Inoperable pancreatic cancer

Standard of care

Kari B. Wisinski, Andrew O Wahl, William Small, Al B. Benson

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Inoperable pancreatic adenocarcinoma is a dilemma that oncologists frequently encounter. Only 15% to 20% of patients are diagnosed when cancer of the pancreas is still surgically resectable. However, pancreaticoduodenectomy is the only curative option for this disease and should be offered to all patients who meet resection criteria and do not have significant comorbidities. For inoperable pancreatic cancer, the goals of treatment are to palliate symptoms and prolong life. Improved survival in locally advanced disease has been demonstrated with chemoradiation plus fluorouracil or with gemcitabine (Gemzar) alone. In metastatic disease, single-agent gemcitabine has been associated with improvement in symptoms and survival. Trials combining various chemotherapeutic agents with gemcitabine have not had a significant impact on overall survival, although meta-analyses suggest a small benefit. The targeted agent erlotinib (Tarceva) has shown a modest improvement in overall survival in combination with gemcitabine. This combination is another option for first-line therapy in patients with locally advanced or metastatic disease. Despite these recent advances, survival for patients with inoperable pancreatic cancer continues to be poor. Future investigations need to focus on understanding the molecular nature of this malignancy, with the goal of developing interventions based on this knowledge.

Original languageEnglish (US)
Pages (from-to)1558-1564
Number of pages7
JournalONCOLOGY
Volume21
Issue number13
StatePublished - Nov 1 2007

Fingerprint

gemcitabine
Standard of Care
Pancreatic Neoplasms
Survival
Pancreaticoduodenectomy
Fluorouracil
Meta-Analysis
Comorbidity
Adenocarcinoma
Therapeutics

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Wisinski, K. B., Wahl, A. O., Small, W., & Benson, A. B. (2007). Inoperable pancreatic cancer: Standard of care. ONCOLOGY, 21(13), 1558-1564.

Inoperable pancreatic cancer : Standard of care. / Wisinski, Kari B.; Wahl, Andrew O; Small, William; Benson, Al B.

In: ONCOLOGY, Vol. 21, No. 13, 01.11.2007, p. 1558-1564.

Research output: Contribution to journalArticle

Wisinski, KB, Wahl, AO, Small, W & Benson, AB 2007, 'Inoperable pancreatic cancer: Standard of care', ONCOLOGY, vol. 21, no. 13, pp. 1558-1564.
Wisinski KB, Wahl AO, Small W, Benson AB. Inoperable pancreatic cancer: Standard of care. ONCOLOGY. 2007 Nov 1;21(13):1558-1564.
Wisinski, Kari B. ; Wahl, Andrew O ; Small, William ; Benson, Al B. / Inoperable pancreatic cancer : Standard of care. In: ONCOLOGY. 2007 ; Vol. 21, No. 13. pp. 1558-1564.
@article{e5b88ca346bc4baba9f71251447b9100,
title = "Inoperable pancreatic cancer: Standard of care",
abstract = "Inoperable pancreatic adenocarcinoma is a dilemma that oncologists frequently encounter. Only 15{\%} to 20{\%} of patients are diagnosed when cancer of the pancreas is still surgically resectable. However, pancreaticoduodenectomy is the only curative option for this disease and should be offered to all patients who meet resection criteria and do not have significant comorbidities. For inoperable pancreatic cancer, the goals of treatment are to palliate symptoms and prolong life. Improved survival in locally advanced disease has been demonstrated with chemoradiation plus fluorouracil or with gemcitabine (Gemzar) alone. In metastatic disease, single-agent gemcitabine has been associated with improvement in symptoms and survival. Trials combining various chemotherapeutic agents with gemcitabine have not had a significant impact on overall survival, although meta-analyses suggest a small benefit. The targeted agent erlotinib (Tarceva) has shown a modest improvement in overall survival in combination with gemcitabine. This combination is another option for first-line therapy in patients with locally advanced or metastatic disease. Despite these recent advances, survival for patients with inoperable pancreatic cancer continues to be poor. Future investigations need to focus on understanding the molecular nature of this malignancy, with the goal of developing interventions based on this knowledge.",
author = "Wisinski, {Kari B.} and Wahl, {Andrew O} and William Small and Benson, {Al B.}",
year = "2007",
month = "11",
day = "1",
language = "English (US)",
volume = "21",
pages = "1558--1564",
journal = "Oncology",
issn = "0890-9091",
publisher = "UBM Medica Healthcare Publications",
number = "13",

}

TY - JOUR

T1 - Inoperable pancreatic cancer

T2 - Standard of care

AU - Wisinski, Kari B.

AU - Wahl, Andrew O

AU - Small, William

AU - Benson, Al B.

PY - 2007/11/1

Y1 - 2007/11/1

N2 - Inoperable pancreatic adenocarcinoma is a dilemma that oncologists frequently encounter. Only 15% to 20% of patients are diagnosed when cancer of the pancreas is still surgically resectable. However, pancreaticoduodenectomy is the only curative option for this disease and should be offered to all patients who meet resection criteria and do not have significant comorbidities. For inoperable pancreatic cancer, the goals of treatment are to palliate symptoms and prolong life. Improved survival in locally advanced disease has been demonstrated with chemoradiation plus fluorouracil or with gemcitabine (Gemzar) alone. In metastatic disease, single-agent gemcitabine has been associated with improvement in symptoms and survival. Trials combining various chemotherapeutic agents with gemcitabine have not had a significant impact on overall survival, although meta-analyses suggest a small benefit. The targeted agent erlotinib (Tarceva) has shown a modest improvement in overall survival in combination with gemcitabine. This combination is another option for first-line therapy in patients with locally advanced or metastatic disease. Despite these recent advances, survival for patients with inoperable pancreatic cancer continues to be poor. Future investigations need to focus on understanding the molecular nature of this malignancy, with the goal of developing interventions based on this knowledge.

AB - Inoperable pancreatic adenocarcinoma is a dilemma that oncologists frequently encounter. Only 15% to 20% of patients are diagnosed when cancer of the pancreas is still surgically resectable. However, pancreaticoduodenectomy is the only curative option for this disease and should be offered to all patients who meet resection criteria and do not have significant comorbidities. For inoperable pancreatic cancer, the goals of treatment are to palliate symptoms and prolong life. Improved survival in locally advanced disease has been demonstrated with chemoradiation plus fluorouracil or with gemcitabine (Gemzar) alone. In metastatic disease, single-agent gemcitabine has been associated with improvement in symptoms and survival. Trials combining various chemotherapeutic agents with gemcitabine have not had a significant impact on overall survival, although meta-analyses suggest a small benefit. The targeted agent erlotinib (Tarceva) has shown a modest improvement in overall survival in combination with gemcitabine. This combination is another option for first-line therapy in patients with locally advanced or metastatic disease. Despite these recent advances, survival for patients with inoperable pancreatic cancer continues to be poor. Future investigations need to focus on understanding the molecular nature of this malignancy, with the goal of developing interventions based on this knowledge.

UR - http://www.scopus.com/inward/record.url?scp=40449111677&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=40449111677&partnerID=8YFLogxK

M3 - Article

VL - 21

SP - 1558

EP - 1564

JO - Oncology

JF - Oncology

SN - 0890-9091

IS - 13

ER -